BridgeBio Pharma Inc. (BBIO)
NASDAQ: BBIO
· Real-Time Price · USD
38.15
-0.42 (-1.09%)
At close: May 05, 2025, 3:59 PM
38.00
-0.39%
After-hours: May 05, 2025, 06:18 PM EDT
-1.09% (1D)
| Bid | 37.54 |
| Market Cap | 7.24B |
| Revenue (ttm) | 127.42M |
| Net Income (ttm) | -667.97M |
| EPS (ttm) | -3.56 |
| PE Ratio (ttm) | -10.72 |
| Forward PE | -14.32 |
| Analyst | Buy |
| Ask | 39.33 |
| Volume | 1,679,112 |
| Avg. Volume (20D) | 3,582,713.5 |
| Open | 38.57 |
| Previous Close | 38.57 |
| Day's Range | 37.76 - 38.67 |
| 52-Week Range | 21.62 - 39.54 |
| Beta | 1.08 |
About BBIO
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-car...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 27, 2019
Employees 725
Stock Exchange NASDAQ
Ticker Symbol BBIO
Website https://www.bridgebio.com
Analyst Forecast
According to 12 analyst ratings, the average rating for BBIO stock is "Buy." The 12-month stock price forecast is $50, which is an increase of 31.06% from the latest price.
Stock ForecastsEarnings Surprise
BridgeBio Pharma has released their quartely earnings
on Apr 29, 2025:
6 days ago
+5.33%
BridgeBio Pharma shares are trading higher after t...
Unlock content with
Pro Subscription
5 days ago
+1.48%
BridgeBio Pharma shares are trading higher after the company reported better-than-expected Q1 financial results.
